DOCSLIB.ORG

Acknowledgements & Contacts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acknowledgements & Contacts page 144 Global Vaccine Action Plan Acknowledgements & Contacts page 145 Acknowledgements & Contacts Approximately 1,100 participants from more than 140 countries and 290 organizations provided ideas, feedback, and comments to the Global Vaccine Action Plan. This document was developed under the auspices of the Decade of Vaccines Collaboration Leadership Council, composed of Seth Berkley (GAVI Alliance), Margaret Chan (World Health Organization), Christopher Elias (Bill & Melinda Gates Foundation), Anthony Fauci (US National Institute of Allergy and Infectious Diseases), Anthony Lake (UNICEF), and 5. Joy Phumaphi (African Leaders Malaria Alliance). page 146 Global Vaccine Action Plan Acknowledgements & Contacts page 147 the deCade of vaccines Collaboration Indonesia), Gina Tambini (the Pan Susan McKinney (USAID), Robert Alliance), Lauren Franzel (PATH), Jennifer Kates (Kaiser Family Research Institute), Adam Sabow steering CoMMittee guided the American Health Organization), Jos Steinglass (John Snow, Inc.), Björn Gillsater (UNICEF), Amanda Foundation), Kaia Lenhart (GMMB), (McKinsey & Company), Chris Wilson deveLopment of the GVAP: Vandelaer (co-chair Delivery Working Liang Xiaofeng (Chinese CDC), Glassman (Center for Global Jesus Lopez-Macedo (UNICEF), (Bill & Melinda Gates Foundation). Pedro Alonso (co-chair DoVC Steering Group, UNICEF), and Sandy John Wecker (PATH), Simon Wright Development), Shanelle Hall Adrian Lovett (ONE), Maziko Matemba Around 110 individuals participated in Committee, the Barcelona Institute Wrobel (co-chair Global Access (Save The Children UK). (UNICEF), Robert Hecht (Results for (Health and Rights Education the discussions of the R&D for Global Health), Ciro de Quadros Working Group, Applied Strategies). Development), Miloud Kaddar (WHO), Program, Malawi), Gregory Poland Working Group. (co-chair DoVC Steering Committee, More than 70 additional individuals Subhash Kapre (retired, the Serum (Vaccine), Kammerle Schneider the Sabin Vaccine Institute), Nicole eight Working grouPs: participated in the discussions of the Institute), Lothe Lene Jeanette (IAVI), Kamel Senouci (Agénce de dov Costing & funding Bates (co-chair Public & Political (Delivery, Global Access, Public & Delivery Working Group, and the (Norwegian Agency for Development Medecine Preventive), Nelson teChniCaL Working grouP: Support Working Group, Bill and Political Support, Research & following resource persons assisted Cooperation), Ian Lewis (UNICEF), Sewankambo (Makerere University), Logan Brenzel (Bill & Melinda Gates Melinda Gates Foundation), Zulfiqar Development, Costing & Funding, the group: Teresa Aguado (WHO), Margie McGlynn (IAVI), Julie Milstien Damian Walker (Bill & Melinda Gates Foundation), Hugh Chang (PATH and Bhutta (Aga Khan University), Lola Health & Economic Benefits, Thomas Cherian (WHO), Rudi (University of Maryland), Neeraj Foundation), Peg Willingham DOVC Secretariat), Santiago Cornejo Dare (The Centre for Health Sciences Monitoring & Evaluation/ Eggers (WHO), Gian Gandhi Mohan (Clinton Health Access (UN Foundation). Over 30 additional (GAVI Alliance), Eliane Furrer (GAVI Training, Research and Development), Accountability Framework Indicators, (UNICEF), Ed Hoekstra (UNICEF), Initiative), Melinda Moree (BIO individuals participated in the Alliance), Lauren Franzel (PATH), Helen Evans (the GAVI Alliance), Lee Communications) involving more Steve Jarrett (UNICEF), Lidija Ventures for Global Health), Mary discussions of the Public and Political Gian Gandhi (UNICEF), Patrick Lydon Hall (National Institute of Allergy than 100 participants have collaborated Kamara (WHO), Patrick Lydon (WHO), C. Muduuli (African Development Support Group. The working group (WHO), Carol Marzetta (Applied and Infectious Diseases), T. Jacob John in the development of the document. Osman Mansoor (UNICEF), Carsten Bank), Raja Rao (Bill & Melinda Gates received support from Stephanie Lazar, Strategies), Helen Saxenian (Results (retired, Christian Medical College, More than additional 180 people Mantel (WHO), Violaine Mitchell Foundation), Daniel Rodriguez (the consultant to the Bill & Melinda Gates for Development), and Sandra Wrobel Vellore, India), Jean-Marie Okwo-Bele participated in the working (Bill & Melinda Gates Foundation), Pan American Health Organization), Foundation, and Lauren Leahy from (Applied Strategies), with consultancy (co-chair Delivery Working Group, group discussions. Dragoslav Popovic (UNICEF), and Helen Saxenian (Results for Develop- the Sandra Rotman Centre. services provided by The Boston the World Health Organization), Orin Daniel Tarantola (WHO). ment), Meredith Shirey (UNICEF), Consulting Group. Levine (co-chair Global Access the folloWing individuaLs have been Maya Vijayaraghavan (CDC), Melinda researCh & deveLopment Working Group, Johns Hopkins MeMbers of the Working grouPs: gLobaL Access Working grouP Wharton (CDC), Piers Whitehead Working grouP Core MeMbers: heaLth & eConoMiC benefits Bloomberg School of Public Health), Core MeMbers: (NeoVacs), Prashant Yadav (University Alex von Gabain (Intercell), Bruce Working grouP: David Salisbury (co-chair Research deLivery Working grouP Girindre Beeharry (Bill & Melinda of Michigan), Michel Zaffran (WHO). Gellin (U.S. Department of Health Jessica Atwell (Johns Hopkins & Development Working Group, Core MeMbers: Gates Foundation), Kim Bush (Bill Johns Hopkins Bloomberg School of and Human Services), Jesse Goodman University), Dagna Constenla (Johns the United Kingdom Department of Amani Abdelmoniem (Ministry of & Melinda Gates Foundation), David Public Health provided the support of (Food and Drug Administration), Hopkins University), S. Deblina Datta Health), Anne Schuchat (National Health, Sudan), Mercy Ahun (the Cook (IAVI), Gerard Cunningham Kyla Hayford to the group. Marie-Paule Kieny (WHO), Margaret (the GAVI Alliance), Ingrid Friberg Center for Immunization and GAVI Alliance), Shams el Arifeen (Bill & Melinda Gates Foundation), Liu (ProTherImmune), Christian (Johns Hopkins University), Marta Respiratory Diseases, the U.S. Centers ICDDRB), Silvia Bino (Institute Harkesh Dabas (Clinton Health PubLiC & PoLitiCaL suPPort Loucq (International Vaccine Gacic-Dobo (WHO), Sue Goldie for Disease Control and Prevention), of Public Health, Albania), Brent Access Initiative), Patricia Danzon Working grouP Core MeMbers: Institute), Adel Mahmoud (Princeton (Harvard School of Public Health), Peter A. Singer (co-chair Public & Burkholder (CDC), Pradeep Haldar (The Wharton School, University of Geoff Adlide (the GAVI Alliance), University), Tom Monath (Kleiner Peter Hansen (the GAVI Alliance), Lisa Political Support Working Group, (Ministry of Health and Family Pennsylvania), James Droop (the U.K. Luis Barreto (retired, Sanofi Pasteur Perkins Caufield & Byers), Gary Nabel Lee (the GAVI Alliance), Orin Levine Sandra Rotman Centre, University Welfare, India), Clifford Kamara Department for International Canada), Shereen El Feki (Global (National Institutes of Health), Regina (Johns Hopkins University), Meredith Health Network and University of (the Sabin Vaccine Institute), Najwa Development), Christopher Egerton- Commission on HIV and the Law), Rabinovich (Bill & Melinda Gates O’Shea (Harvard School of Public Toronto), Lucky Slamet (the National Khuri-Bulos (Jordan University Warburton (Lion’s Head Global Part- David Gold (Global Health Strategies), Foundation), Rino Rappuoli Health), Sachiko Ozawa (Johns Agency of Drug and Food Control, Hospital), Rebecca Martin (CDC), ners), David Ferreira (the GAVI Elizabeth Gore (UN Foundation), (Novartis Vaccines & Diagnostics), Hopkins University), Susan Reef Steve Reed (Infectious Diseases page 148 Global Vaccine Action Plan (CDC), Meghan Stack (Johns Hopkins The World Health Assembly in May Alabaster (Communications), Questions about the Global Vaccine Action Plan can University), Peter Strebel (WHO), 2011 and the WHO Executive Board Dan Epstein (Communications), Chutima Suraratdecha (PATH), in January 2012 reviewed the initial Joan Tallada (CSOs Coordinator), be directed to representatives from the Decade of Steven Sweet (Harvard School of drafts of the GVAP and provided Claudia Hernandez (Project Vaccines Collaboration Leadership Council agencies. Public Health), Yvonne Tam valuable inputs and guidance on the Assistant), Yolanda Amat (Project (Johns Hopkins University), Emilia process and the content of the GVAP. Assistant), Desirée Van der Mei Vynnycky (Health Protection Agency), (Project Assistant), Monique Shields Damian Walker (Bill & Melinda UNICEF organized a briefing of (Project Assistant). Gates Foundation), Neff Walker UN member states representatives (Johns Hopkins University), Steve on the 19 January 2012 in New York. The Steering Committee members Wiersma (WHO). Appendix 5 contains a list of all endorse the Global Vaccine Action countries and organizations that have Plan and generally agree with its Monitoring & evaLuation/ contributed to the document. findings. The document represents Bill & Melinda Gates Foundation GAVI Alliance National Institute of Allergy and AccountabiLity fraMeWork a common vision of the Steering Email: [email protected] Email: [email protected] Infectious Diseases (NIAID) indiCators Working grouP: The DoV Collaboration Secretariat Committee, incorporating inputs from Email: [email protected] David Brown (UNICEF), Tony Burton was responsible for preparing and members of the different working (WHO), John Grove (Bill & Melinda managing the consultation process groups, academia,
Load more

Recommended publications
  • Independent Monitoring Board of the Global Polio Eradication Initiative Report
    Independent Monitoring Board of the Global Polio Eradication Initiative Report July 2011 Independent This second report follows our third meeting, held in London on 30 June and 1 July 2011. Monitoring Board of the At present the needs are: Global Polio • To concisely understand the global situation Eradication Initiative • To maintain clear and energetic focus in each country with ongoing transmission July 2011 • To see the wood for the trees in identifying and dealing with the programme’s key risks • To find innovative solutions that break through entrenched problems • To surface fundamental problems that need urgent attention We are grateful to the many partners of the Global Polio Eradication Initiative who have provided us with information, logistical support, and valuable insights. We are grateful for their help, and commend their commitment. Our role remains to speak with a clear, objective voice that is independent of any of these partners. We each sit on this board in a personal capacity. We remain resolutely independent, and will continue to present our frank view without fear or favour. Sir Liam Donaldson (Chair) Dr Mushtaque Chowdhury* Former Chief Medical Officer, England Associate Director, Rockefeller Foundation Dr Nasr El Sayed Dr Ciro de Quadros Assistant Minister of Health, Egypt Executive Vice President, Sabin Vaccine Institute Dr Jeffrey Koplan Dr Sigrun Mogedal Vice President for Global Health Special Advisor, Norweigan Knowledge Centre Director, Emory Global Health Institute for the Health Services Professor Ruth Nduati Dr Arvind Singhal Chairperson, Department of Paediatrics and Child Health Marston Endowed Professor of Communication University of Nairobi University of Texas at El Paso Professor Michael Toole Head, Centre for International Health *Dr Chowdhury was unable to participate in the meeting but Burnet Institute, Melbourne endorses this report The Independent Monitoring Board was convened at the request of the World Health Assembly to monitor and guide the progress of the Global Polio Eradication Initiative’s 2010-12 Strategic Plan.
    [Show full text]
  • THE ERADICATION of POLIOMYELITIS (Fhe Albert V.• Sabin Lecture)
    THE ERADICATIONOF POLIOMYELITIS (fhe Albert V.•Sabin Lecture) by Donald Henderson, M.D., M.P.H. University Distinguished Service Professor The JohnsHopkins University Baltimore, Maryland 21205 Cirode Quadros, M.D., M.P.H. Regional Advisor Expanded Programme on lmmunii.ation Pan American Health Organization 525 23rd Street, N. W. Washington, D.C. 20037 Introduction The understanding and ultimate conquest of poliomyelitis was Albert Sabin's life­ long preoccupation, beginning with his earliest work in 1931. (Sabin and Olitsky, 1936; Sabin, 1965) The magnitude of that effort was aptly summarized by Paul in his landmark history of polio: "No man has ever contributed so much effective information - and so continuously over so many years - to so many aspects of poliomyelitis." (Paul, 1971) Thus, appropriately, this inaugural Sabin lecture deals with poliomyelitis and its eradication. Polio Vaccine Development and Its Introduction In the quest for polio control and ultimately eradication, several landmarks deserve special mention. At the outset, progress was contingent on the development of a vaccine and the production of a vaccine, in turn, necessitated the discovery of new methods to grow large quantities of virus. The breakthrough occurred in 1969 when Enders and his colleagues showed that large quantities of poliovirus could be grown in a variety of human cell tissue cultures and that the virus could be quantitatively assayed by its cytopathic effect. (Enders, Weller and Robbins, 1969) Preparation of an inactivated vaccine was, in principle, a comparatively straightforward process. In brief, large quantities of virus were grown. then purified, inactivated with formalin and bottled. Assurance that the virus had been inactivated could be demonstrated by growth in tissue.
    [Show full text]
  • KDHE News Release
    News Room - 2012 - News Release A to Z Topic Listing KDHE News Release For Immediate Release KDHE Office of Communications January 3, 2012 [email protected], 785-296-0461 KDHE Promotes Cancer Screenings and HPV Vaccination During Cervical Health Awareness Month TOPEKA – In recognition of Cervical Health Awareness Month, the Kansas Department of Health and Environment (KDHE) encourages women to schedule their annual well-woman checkups. According to a 2010 Kansas Behavioral Risk Factor Surveillance System (BRFSS) report, approximately 17 percent of Kansas women aged 18 and older did not have a Pap test within the past three years. "Pap tests decrease the risk of developing cervical cancer by detecting precancerous cells which, when found early, are highly treatable," said Robert Moser, M.D., KDHE Secretary and State Health Officer. “Women should have their first screening Pap test at age 21, or within three years of becoming sexually active if younger." Although cervical cancer was once the leading cancer killer of women, the number of cases has declined 75 percent in the past 50 years, largely because of the widely available and reliable Pap test. Even so, an estimated 12,000 women in the United States are diagnosed with cervical cancer each year. In 2007, 4,021 women died from cervical cancer in the United States. In 2008, 76 Kansas cases were diagnosed, with 24 deaths due to cervical cancer in 2010. Most cervical cancer cases are caused by infection with human papillomavirus (HPV), a common sexually transmitted disease. HPV infection can also cause a number of other health problems for both men and women.
    [Show full text]
  • CV Seth Berkly2.Indd
    Dr Seth Berkley Chief Executive Officer of the GAVI Alliance As a physician, epidemiologist and leading advocate for vaccines and immunisation, Dr Seth Berkley brings many years of experience and knowledge from the fields of public health, development and vaccines to the work of the Alliance. Seth joined the GAVI Alliance in August 2011 as it launched its five year strategy to immunise a quarter of a billion children in the developing world with life-saving vaccines by 2015. “I am impressed by GAVI’s life-saving work and have great admiration for its successful track record,” said Dr Berkley. “I am therefore honoured and excited to have been chosen to lead the GAVI Alliance as it works to deliver on an ambitious new strategy.” Prior to joining the GAVI Alliance, Seth was the founder, president and CEO for 15 years of the International AIDS Vaccine Initiative ( IAVI ), the first vaccine product development public-private sector partnership. Under his leadership, IAVI implemented a global advocacy programme that assured that vaccines received prominent attention in the media and in political forums such as the G 8, EU and the UN. He also oversaw the creation of a virtual vaccine product development effort involving industry, academia, and developing country scientists. Prior to founding IAVI, Seth served as associate director in the Health Sciences Division at The Rockefeller Foundation. He has also worked for the Center for Infectious Diseases of the U. S. Centers for Disease Control and Prevention ( CDC ), the Massachusetts Department of Public Health and for the Carter Center where he served as an epidemiologist at the Ministry of Health in Uganda.
    [Show full text]
  • Fall 2011 MEDICINE
    BROWN Volume 17 | Number 3 | Fall 2011 MEDICINE Gentleman Scholar Calm, cool, connected, Griffin Rodgers pushes for research that will serve the people. PS:l U PRIMARY CARE REIMAGINED MAKING BABIES c1BrMed_Spring11rev.indd 1 9/29/11 1:53 PM Letter from the dean Start of One Era, End of Another The opening of the new Medical School in Providence’s old Jewelry District on August 15 marked one of the most important mile- stones in our history. Now our students have a state-of-the-art, spacious, and absolutely stunning home to call their own. This his- toric, creatively restored building off Col- lege Hill is close to several of our major teaching hospitals and the Public Health Program. Furthermore, it symbolizes Brown’s commitment to the city and the state to educate the next generation of physicians for all of us. Reunion and Commencement were carried out with beautiful weather and our usual traditions. Alumnus Griffin P. Rodgers, director of the National Institute of Diabetes and Digestive and Kidney Diseases—one of the National Institutes of Health—gave an inspiring commencement speech to our graduating class and is featured in this issue. He emphasized the excitement of research in human biology in this era of genomics, proteomics, and systems biology. Advances over the next decades will be spectacular and will change the way we care for patients. Since the earliest classes, the Medical School’s graduates have enhanced the lives of their patients as well as their communities. Some, such as Dr. Rodgers, have gone on to national careers.
    [Show full text]
  • Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the Global Vaccine Markets
    Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets DCVMN 18th AGM Seth Berkley M.D, CEO 26 September 2017, Seoul www.gavi.org Gavi’s mission, model and 1 achievements to date Gavi’s mission Saving by increasing and protecting in lower-income children’s equitable use of people’s health countries lives vaccines DCVMN 18th AGM 26 September 2017 Gavi’s partnership model IMPLEMENTING COUNTRY DONOR COUNTRY GOVERNMENTS GOVERNMENTS CIVIL SOCIETY RESEARCH & ORGANISATIONS TECHNICAL AGENCIES VACCINE PRIVATE MANUFACTURERS SECTOR PARTNERS DCVMN 18th AGM 26 September 2017 Increasing immunisation coverage Launch of Gavi Post-Gavi 20% increase points 2000-2016 1980 1985 1990 1995 2000 2005 2010 2016 2020 Expanded Programme Stall in immunisation Support from Gavi to world’s on Immunization takes off coverage lowest-income countries * Based on data officially reported to WHO and UNICEF by current member states. Note: Includes DTP-containing vaccines, such as pentavalent vaccine. th Source: WHO/UNICEF Estimates of National Immunization Coverage, 2017 DCVMN 18 AGM 26 September 2017 Accelerating access to new vaccines in poorest countries Prior to Gavi support Now High-income countries Low-income countries High-income countries Low-income countries 100% 100% 100% 91% 86% 86% 77% 72% Hepatitis B 67% Hib Pneumococcal % of countries introduced vaccines nationally 3% 6% 6% 2000 2009 2000 2009 2016 Note: Only countries with universal national introduction are included. World Bank 2016 country classification has been applied to the whole time series. DCVMN 18th AGM Source: The International Vaccine Access Center (IVAC) VIMS database. Data as of 31 December 2016.
    [Show full text]
  • Leadership in Global Health: the Case of Ciro De Quadros, a Testament to Values, Valor, and Vision
    Pan American Journal Profile of Public Health When Dr. Bill Foege wrote “When Words Fail,” he was referring to how difficult Leadership in it was for him to describe adequately, in written words, all the effort that is involved from the scientific conceptualization of a new vaccine, to eventual bench discovery global health: and development, to the training and supply chain logistics, and ultimately to the moment the needle pricks the skin to save a life of a child (1). He called it the “chain the case of Ciro of perfection”. He was “at a loss” to describe this cascade of events with due justice. I have been asked to describe the leadership attributes of Dr. Ciro de Quadros as a de Quadros, a case study in best practice and lessons to be learned. Similarly, I too am at a loss. Simply put, Ciro broke the mold. testament to I should disclose that what I am about to write is influenced by decades of either working directly for Ciro, as was the case during the polio eradication era in the Americas, to collaborating with Ciro more recently on various projects that in- values, valor, cluded measles and rubella elimination, the introduction of new vaccines, and sur- veillance of infectious diseases. The work evolved into a relationship that bridged and vision from professional mentorship, to actual friends with a deep sense of admiration, love, and mutual respect. In global health, leadership is somewhat like the “self-actualization” of public Jon Kim Andrus1 health practice. The “leader” must have all those attributes that embodies a fully realized individual, positioned in the system to make things happen, such as in Ciro’s case, to help create a world of equitable access to life-saving vaccines.
    [Show full text]
  • Seth Berkley MD
    Seth Berkley M.D. Chief Executive Officer of the GAVI Alliance Seth Berkley joined the GAVI Alliance as CEO in August 2011, as it launched its five year strategy to immunise a quarter of a billion children in the developing world with life-saving vaccines by 2015. Prior to joining the GAVI Alliance, Seth was the founder, president and CEO for 15 years of the International AIDS Vaccine Initiative ( IAVI ), the first vaccine product development public-private sector partnership. Under his leadership, IAVI implemented a global advocacy programme that assured that vaccines received prominent attention in the media and in forums such as the G 8, EU and the UN. He also oversaw the creation of a virtual vaccine product development effort involving industry, academia, and developing country scientists. Prior to founding IAVI, Seth served as associate director in the Health Sciences Division at The Rockefeller Foundation. He has also worked for the Center for Infectious Diseases of the U. S. Centers for Disease Control and Prevention ( CDC ), the Massachusetts Department of Public Health and for the Carter Center where he served as an epidemiologist at the Ministry of Health in Uganda. He has consulted or worked in more than 25 countries in Asia, Africa and Latin America. Seth sits on a number of international steering committees and corporate and not-for-profit boards, including those of Gilead Sciences, the New York Academy of Sciences and the Acumen Fund. In the past, he has also served on the boards of public and private vaccine companies such as PowderJect and VaxInnate and health and development organisations such as OXFAM America.
    [Show full text]
  • COVID-19 Vaccine Development, Strategy and Implementation
    Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability.
    [Show full text]
  • 2021 GTFCC World Health Assembly Side Event 20 May 2021 Biographies: Speakers and Moderators
    2021 GTFCC World Health Assembly Side Event 20 May 2021 Biographies: Speakers and Moderators 1 Biographies: Table of Contents Dr. Tedros Adhanom Ghebreyesus..................................................................................... 3 Dr. Frew Benson ............................................................................................................... 4 Dr. Seth Berkley ............................................................................................................... 5 Dr. Christopher R. Braden.................................................................................................. 6 Dr. Godfrey Bwire ............................................................................................................. 7 Mr. Emanuele Capobianco ................................................................................................ 8 Ms. Simone Carter ............................................................................................................ 9 Mr. Wiseman Chimwaza ................................................................................................. 10 Ms. Pamela Mwelala Chisanga ....................................................................................... 11 Dr. Marc Gastellu-Etchegorry .......................................................................................... 12 Christine Marie George, PhD ........................................................................................... 13 Dr. Myriam Henkens ......................................................................................................
    [Show full text]
  • 2010 Albert B. Sabin Gold Medal Awarded to Dr. John D. Clemens
    Home About Us Press Room Support Sabin Michael Marine May 2010 Appointed CEO of The Sabin Report | Volume 12 Issue 2 Sabin Vaccine Institute 2010 Albert B. Sabin Gold Medal Awarded to Dr. John D. Clemens During a ceremony at The George Washington University City View Room, Dr. John D. Clemens, Director General of the International Vaccine Institute in Seoul, Korea, received the 2010 Albert B. Sabin Gold Medal Award for his contributions to reducing suffering and promoting peace Dr. Steven Knapp, The George Washington through the development, University President; Dr. John D. Clemens; evaluation, and distribution of and Dr. Peter Hotez, Sabin President and Michael W. Marine, former The George Washington University vaccines. Distinguished Research Professor US Ambassador to the Socialist Republic of Dr. Clemens led the first efficacy trial of an oral vaccine against Vietnam, was appointed as cholera, and conducted additional research on a measles vaccine as the new chief executive a research scientist at the International Center for Diarrhoeal Disease officer of the Sabin Research, Bangladesh during the 1980s. IVI scientists transferred Vaccine Institute on April the technology for the cholera vaccine to Shantha Biotechics of 28, announced Sabin's Hyderabad, India, and in 2009, Shanchol™ was licensed for Chairman of the Board of development. Trustees, Mort Hyman and President Dr. Peter Hotez. Through his stewardship at the International Vaccine Institute in Seoul, Korea where he has served as Director General since 1999, Marine joined Sabin's Dr. Clemens has engaged in vaccine diplomacy in many areas, leadership team in including the Democratic People's Republic of Korea Program, which December 2009 after aims to reduce the disease burden of Hib and Japanese encephalitis serving eight months on in North Korean children by providing technical assistance in the Joint Action Committee laboratory diagnosis and surveillance of these diseases and in the of the Global Network for introduction of vaccines to prevent them.
    [Show full text]
  • (GIN) Global Immunization News
    Global Immunization News (GIN) Global Immunization News (GIN) May 2019 In this issue News You can click on the article 72nd World Health Assembly Special Report you are interested in and ac- Hayatee Hasan, WHO Headquarters cess it directly! This year’s World Health Assembly was held from 20 News to 28 May 2019 at the Palais des Nations in Geneva, • Immunization Agenda 2030 2 Switzerland and was attended by nearly 4000 delegates • Advancing digital health in 2 from WHO’s 194 Member States and partner organiza- Bangladesh through electron- ic immunization registration tions. The general theme of this year’s World Health • The world’s first malaria 3 Assembly (WHA) was "Universal health coverage: leav- vaccine highlighted at ing no-one behind”. #WHA72 The Assembly Hall at the Palais des Nations 3 in Geneva, Switzerland. • Malaria vaccine pilot Key highlights included: launched in Ghana • WHO announced the appointment of four new goodwill ambassadors from the fields of sports, • Over 100 000 people sick 3 with measles in 14 months: politics and community mobilization to promote healthier lives, stronger health workforces and with measles cases at an improved mental health globally. The new ambassadors are: alarming level in the Europe- 1. Alisson Becker, goalkeeper of the Brazilian national and Liverpool football teams; an Region, WHO scales up 2. Dr Natália Loewe Becker, medical doctor and health advocate from Brazil, as WHO response Goodwill Ambassadors for Health Promotion; • WHO adapts ebola vaccina- 4 tion strategy in the Demo- 3. Cynthia Germanotta, President of Born This Way Foundation, which was co-founded cratic Republic of the Congo with her daughter Lady Gaga, as WHO Goodwill Ambassador for Mental Health; and to account for insecurity and 4.
    [Show full text]